سعر فوليفاكتور 75 وحدة دولية فيال 2022

Recombinant follicle-stimulating hormone (follitropin) 75 IU vial for infertility treatment, listed in Egypt under Biofactor GmbH (Germany) / Marcyrl.

• Most common (>=5%): ovulation induction - headache, abdominal pain, ovarian hyperstimulation; ART - abdominal pain, nausea, abdominal enlargement, headache, injection-site bruising.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Contraindicated with prior hypersensitivity to recombinant FSH products; high FSH levels indicating primary gonadal failure; uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary); sex hormone-dependent tumours of the reproductive tract; pituitary or hypothalamic tumours; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement not due to PCOS.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Should be used only by physicians experienced in infertility treatment with appropriate monitoring; can cause ovarian hyperstimulation syndrome (OHSS) with or without pulmonary or vascular complications, abnormal ovarian enlargement, ovarian torsion and multi-fetal gestation; hypersensitivity reactions including anaphylaxis have been reported. Use the lowest effective dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Ectopic pregnancy and spontaneous abortion risks may be increased in women treated with gonadotropins/ART; congenital malformations and ovarian neoplasms are addressed in the label warnings.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Not indicated in pregnant women; there are no human data that gonadotropins alone or as part of IVF/ICSI increase the risk of congenital malformations.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; women are advised not to breastfeed during treatment because prolactin secretion can reduce ovarian response.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Gonadotropin therapy requires the availability of appropriate monitoring facilities to manage the risks of OHSS and multiple pregnancy.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

English text not available for this section.